next generation sequencing based test (Foundation Medicine Inc)
99
Structured Review
Foundation Medicine Inc
next generation sequencing based test
Next Generation Sequencing Based Test, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2432 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+test/FoundationOne+CDx/pmc12578505-138-3-8
Average 99 stars, based on 2432 article reviews
Next Generation Sequencing Based Test, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2432 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+based+test/FoundationOne+CDx/pmc12578505-138-3-8
Average 99 stars, based on 2432 article reviews
next generation sequencing based test - by Bioz Stars,
2026-11
99/100 stars
Images
Related Articles
Sequencing:Article Title: Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer Article Snippet: FIRST is testing HRD status ( BRCA1/2 mutation and genomic instability) of patient tumor tissue samples using the MyChoice HRD plus CDx Assay (Myriad Genetics, Salt Lake City, UT, USA), PD-L1 status of patient tumor tissue samples using the VENTANA SP263 immunohistochemistry assay (Roche Diagnostics, Indianapolis, IN, USA), and circulating tumor DNA (ctDNA) for HRR mutations ( BRCA m; BRCA wt HRR positive; BRCA wt HRR negative/not determined) using the ResBio ctDX-HRR assay (Resolution Bioscience, Inc, Kirkland, WA, USA). .. ATHENA uses the Mutagenesis:Article Title: Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer Article Snippet: FIRST is testing HRD status ( BRCA1/2 mutation and genomic instability) of patient tumor tissue samples using the MyChoice HRD plus CDx Assay (Myriad Genetics, Salt Lake City, UT, USA), PD-L1 status of patient tumor tissue samples using the VENTANA SP263 immunohistochemistry assay (Roche Diagnostics, Indianapolis, IN, USA), and circulating tumor DNA (ctDNA) for HRR mutations ( BRCA m; BRCA wt HRR positive; BRCA wt HRR negative/not determined) using the ResBio ctDX-HRR assay (Resolution Bioscience, Inc, Kirkland, WA, USA). .. ATHENA uses the Expressing:Article Title: Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer Article Snippet: FIRST is testing HRD status ( BRCA1/2 mutation and genomic instability) of patient tumor tissue samples using the MyChoice HRD plus CDx Assay (Myriad Genetics, Salt Lake City, UT, USA), PD-L1 status of patient tumor tissue samples using the VENTANA SP263 immunohistochemistry assay (Roche Diagnostics, Indianapolis, IN, USA), and circulating tumor DNA (ctDNA) for HRR mutations ( BRCA m; BRCA wt HRR positive; BRCA wt HRR negative/not determined) using the ResBio ctDX-HRR assay (Resolution Bioscience, Inc, Kirkland, WA, USA). .. ATHENA uses the |